Career & Filing History
Every role Jennifer Jarrett has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Jennifer Jarrett is a corporate insider at Zura Bio Ltd (ZURA). Jarrett has also held reporting roles at Sagimet Biosciences Inc. (SGMT) and Damora Therapeutics, Inc. (DMRA). Jarrett has reported 9 insider filings with the SEC since 2024. The most recent filing was in June 2026.
Every role Jennifer Jarrett has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Zura Bio Ltd (ZURA)1 filingSagimet Biosciences Inc. (SGMT)1 filingUpdated Aug 30, 2026
Jennifer Jarrett files SEC Form 4 reports at Zura Bio Ltd (ZURA). 9 SEC Form 4 filings on record going back to 2024, most recently on 22 June 2026. Most recent open-market trade: sold $954K of RCUS on 12 November 2025. Lifetime open-market sales: $1.70M.
Every recent SEC Form 4 transaction Jennifer Jarrett has reported, most recent first.
InsiderAlpha's records for Jennifer Jarrett go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 9 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Jennifer Jarrett files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Jennifer Jarrett is a corporate insider of Zura Bio Ltd (ZURA). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases and 3 open-market sales ($1.70M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$RCUS Arcus Biosciences, Inc.31.0K shares @ $0.00-